A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia
Clinical trial NCT05502549 · COMPLETED
Trial details
- NCT number
- NCT05502549
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-29
- Primary completion
- 2023-11-09
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.